1upHealth provides the healthcare industry’s most sophisticated FHIR-enabled health data platform for claims and clinical data acquisition, exchange, and compute. From leading health plans and state Medicaid agencies to innovative digital health organizations and top-performing ACOs, over 75 health organizations rely on 1upHealth to meet evolving regulatory requirements and optimize claims and clinical data-driven initiatives. With the push towards digital quality measures, population health analytics, value-based contracts, and better healthcare experiences, the 1up managed platform helps our customers to meet the growing demands for data access and connectivity. For more information, visit www.1up.health.

Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination, we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.

Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel de Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis, and management of disease.

Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our Protein Nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-Designed Therapies (ART) platform is created to address key limitations of conventional gene therapies by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world. As an early employee, you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast, and fun. Our brand new site includes state-of-the-art lab space and equipment, a healthy café, an outdoor patio, a state-of-the-art gym/yoga studio, a lounge (pool table/golf simulator), free/plentiful parking, and more.

Meet Albert, the faster way to innovate. Everyday Albert’s end-to-end platform empowers thousands of scientists across 30+ countries to accelerate R&D and get products to market faster. Built for innovators, by innovators, Albert was designed from the ground up to remove innovation barriers caused by siloed and disconnected systems in the lab. The result? One platform for the entire R&D team—scientists, technicians, engineers, and managers—delivering the data-driven insights and productivity tools needed to achieve better results in the lab.

Alluvial is the software development company supporting the development of the Liquid Collective protocol. We're focused on the overall growth and maturity of the ecosystem by fostering participation in proof of stake blockchains.

Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt, and respond to a patient’s individual signals, thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, MedTech industry professionals, and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The company was spun out from the University of Oxford in 2021 and is backed by Oxford Science Enterprises and 8VC.

Our mission: Access. Be the definitive specialty care platform that connects every medical facility to the specialty care they need to improve patient outcomes.

AppliedVR is creating a new reality in healthcare. We are pioneering Immersive Therapeutics (ITx), a new category of medicine, to treat intractable health conditions such as chronic pain and behavioral and mental health disorders that affect millions of people worldwide. Today, AppliedVR's treatments represent a comprehensive approach to chronic pain that empowers patients with an intuitive device they can self-manage at home. AppliedVR's RelieVRx is the first VR-based, prescription therapeutic to receive Breakthrough Therapy Designation and De Novo Authorization by the FDA for chronic lower back pain (CLBP). In addition to RelieVRx, AppliedVR's pain management and wellness programs have been trusted by more than 200 leading health systems and thousands of healthcare professionals globally, treating more than 60,000 patients.

Argyle is the payroll connectivity platform for modern financial services. We provide fast, cost-effective, consumer-permissioned access to the most trusted network for real-time income and employment data. With Argyle, businesses automate verifications and background checks, fund accounts, switch direct deposits, calculate premiums, advance wages, and build more exceptional experiences for their customers. Founded in 2018, Argyle’s coverage of U.S. consumers is superior to the three largest credit bureaus and delivers hit rates 4 to 5x higher than all other data providers at a fraction of the cost.